Clinical Trials Browser

Phase 2 × Neuroendocrine Tumors × pasireotide × Clear all

NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase 2 Completed

29 enrolled 11 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors